Most patients with heart failure with reduced ejection fraction (HFrEF) who start taking four different classes of drugs within one month of their diagnosis do best, says the American College of Cardiology (ACC) and Heart Failure Society of America (HFSA). The four drugs are angiotensin receptor/neprilysin inhibitors (ARNI); beta-blockers; mineralocorticoid receptor antagonists (MRA, also called aldosterone antagonists); and sodium-glucose cotransporter 2 (SGLT2) inhibitors.
To continue reading this article or issue you must be a paid subscriber. Sign in
Subscribe to Heart Advisor
Get the next year of Heart Advisor for just $20. And access all of our online content - over 2,000 articles - free of charge.
Subscribe today and save 38%. It's like getting 5 months FREE!
